Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NASSIST: Atezolizumab in Superior Sulcus NSCLC
NCT04989283Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Sep 2021
- Primary completion
- May 2031
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Planned start Sep 2021; status: withdrawn.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04989283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04989283.